Cisplatin radiosensitizes radioresistant human mesenchymal stem cells

Area of Science:

• Oncology
• Stem Cell Biology
• Radiotherapy Research

Background:

• Cisplatin-based chemo-radiotherapy is a standard cancer treatment but causes severe late toxicities.
• Mesenchymal stem cells (MSCs) can regenerate tissues damaged by cisplatin or radiation.
• The impact of combined chemo-radiotherapy on MSCs is not well understood.

Purpose of the Study:

• To investigate the effect of cisplatin-based chemo-radiotherapy on human bone marrow-derived MSCs.
• To determine if cisplatin influences MSC radiosensitivity and stem cell properties.
• To explore the clinical implications of these findings on late toxicities.

Main Methods:

• Human bone marrow-derived MSCs were treated with varying doses of cisplatin.
• MSCs were subsequently exposed to radiation.
• Assessed MSC radiosensitivity, apoptosis, cell cycle, DNA damage, motility, adhesion, surface markers, and differentiation potential.

Main Results:

• Cisplatin dose-dependently increased MSC radiosensitivity and radiation-induced apoptosis.
• MSC stem cell properties (motility, adhesion, markers, differentiation) remained largely unaffected.
• Increased radiosensitivity correlated with a G2/M cell cycle shift and elevated DNA double-strand breaks.

Conclusions:

• Cisplatin confers a dose-dependent radiosensitization effect on human MSCs.
• This radiosensitization may lead to a loss of regenerative MSCs post-treatment.
• The findings suggest a potential mechanism contributing to severe late toxicities in cancer patients.